A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany

A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany

Abstract Background: A total of 62/66 (93.9%) residents in a senior citizen home in Bremen, Germany, received the first dose of the Biontech/Pfizer vaccine BNT162b2 on December 27th 2020. After routine severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antigen tests showed positive results...

Full description

Bibliographic Details
Main Authors: Rolf Schwarzer, Sabine D. Freys, Nick Neuwinger, Nina Beikert, Bettina Eberspächer, Anke Edelmann, Marta Zuchowski, Inga Slothouwer, Angela Stein, Kathrin Theil, Peter Menzel, Jörg Hofmann
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Immunity, Inflammation and Disease
Subjects:
infections
processes
vaccination
viral/retroviral
Online Access:https://doi.org/10.1002/iid3.532

Internet

https://doi.org/10.1002/iid3.532

Similar Items